United Nations E/CN.7/2001/3

Economic and Social Council

Distr.: General
5 February 2001

Original: English

Commission on Narcotic Drugs
Forty-fourth session
Vienna, 20-29 March 2001
Item 5 (a) of the provisional agenda*
Drug demand reduction: Action Plan for the Implementation of the Declaration on the Guiding Principles of Drug Demand Reduction

Revision of part II of the annual reports questionnaire

Note by the Secretariat

1. In its resolution 43/1, entitled "Streamlining the annual reports questionnaire", the Commission on Narcotic Drugs decided to abolish sections 2 and 3 of part II of the annual reports questionnaire, since those sections duplicated the new biennial questionnaire for reporting on the action plans and measures adopted by the General Assembly at its twentieth special session.

2. In resolution 43/1, the Commission requested the Executive Director of the United Nations International Drug Control Programme to revise section 1 of part II of the annual reports questionnaire, and to test the resulting draft questionnaire in countries with various levels of development with regard to data-collection capacity.

3. The Commission also requested the Executive Director to use information technology, as part of the revision process, to assist countries with more efficient submission of the annual reports questionnaire on drug abuse, and to submit to the Commission on Narcotic Drugs at its forty-fourth session a draft of the revised annual reports questionnaire for examination with a view to introduction in 2002.

4. The draft of the revised part II of the annual reports questionnaire, entitled "Extent, patterns and trends of drug abuse", is annexed for the consideration of the Commission.

*E/CN.7/2001/1.

V.01-80642 (E) 120201 130201

LOGO

Annual Reports Questionnaire

Part II
Drug Abuse

Extent, patterns and trends of drug abuse

Report of the Government of _____

Reporting Year _____

Name, address, telephone, telex, fax and e-mail of the person responsible for national drug abuse data in the country.

Name _____

Title/position _____

Address _____

_____

Telephone _____ **Telex** _____

Fax _____ **E-mail** _____

Name, position, address, telephone, telex, fax and e-mail of the technical person responsible for the completion of Part II, *if different from above.*

Name _____

Title/position _____

Address _____

_____

Telephone _____ **Telex** _____

Fax _____ **E-mail** _____

The completed questionnaire should be addressed to:

The Secretary-General
United Nations International Drug Control Programme
Vienna International Centre
PO Box 500
A-1400 Vienna, Austria

Structure of the questionnaire

This questionnaire contains the following sections:

1
Prevalence of drug abuse among the general population, *pages 1-4, questions Q1-Q9*

2
Prevalence of drug abuse among the school (youth) population, *pages 5-6, questions Q10-Q14*

3
Injecting drug abuse, *pages 7-8, questions Q15-Q22*

4
Severe drug abuse, *page 9, questions Q23-Q28*

5
New developments in prevelence and patterns of drug abuse, *pages 10-11, questions Q29-Q32*

6
Drug-related morbidity, *page 12, questions Q33-Q38* .

7
Drug-related mortality, *pages 13-14, questions Q39-Q47*

8
Drug treatment, *pages 15-16, questions Q48-Q58*

9
Data collection capacity, *page 17, questions Q59-Q61*

The sections ask for information at two distinguished levels, which recognises the fact that at present many countries do not yet have detailed data on these topics.

- **Summary expert opinions**
  The questions at this level ask for broad general 'qualitative' information. All questions refer to the past year, being the reporting period.The questions do not require actual data; if you have no data based on surveys, registers or formal estimation methods, the questions can be answered on the basis of the opinions of informed experts. *This should allow all countries to respond.*

- **Quantitative estimates**
  The questions at this level ask for quantitative statistical estimates. The ARQ includes standardized response categories – *the Global Standardized Data-set (GSD).* However, should your data not conform to these categories they can still be included. Please simply indicate the categories used (for example age-range, drug category) in the space provided.

  Estimates should be provided for the reporting year. Where this is not possible please include the most appropriate recent figures available. You should always specify the year of the estimate.

  If you do not have a national estimate you can specify an estimate for a part of the country or for a sub-population. If you have more than one of such partial estimates, you should take the estimate that in your opinion is the best alternative for a recent national estimate. In such case you should also specify the geographical or population coverage of the estimate as simply but explicit as possible, as well as the size of the reference population.

  For easy recognition a different background colour is used for quantitative estimates.

General instructions for completion

- Many questions have pre-coded response categories and you only have to mark the appropriate boxes. Most other questions require to fill in rank order numbers, numbers or percentages.

- Several questions relate to drug classes or drug types. Whenever applicable, it is important that the information requested is reported for individual drugs. Although we have taken care to include all major drugs relevant for the topic concerned, the pre-coded lists might not fully suit the interests of your country. We therefore provide in each list the opportunity to add other drug classes or drug types. You may use these open categories also to insert alternative aggregate groups of drugs.
  For example: some questions list 'heroin' and 'other opioids', if you only have information on all opioids, you should specify 'all opioids' as 'other drugs'.

- In all tables you should leave cells blank if you do not know the answer or cannot provide the required figure. All empty cells will be interpreted as 'no information available'. If a figure would result in the value zero, please specify this as 0.

- Instructions for specific questions are provided in green boxes alongside the questions. In several places in the questionnaire we have provided open text boxes to add remarks and comments on the topic. For this purpose you can also use the empty pages at the end of the questionnaire.

- For further notes and definitions of technical terms used in this form please refer to the accompanying *'The ARQ, a Lexicon of Terms and Guidance Notes'.*

Class of drugs / Type of drugs	Q1 Has there been significant use in the past year? NO	Q1 YES	Q2 How are main drug classes ranked in order of prevalence? Put in numerical order	Q3 Within each drug class separately, how are drug types ranked in order of prevalence? Put in numerical order
Cannabis type	☐	☐	☐	
Marihuana	☐	☐		☐
Hashish	☐	☐		☐
Opioids	☐	☐	☐	
Heroin	☐	☐		☐
Opium	☐	☐		☐
Other	☐	☐		☐
Cocaine type	☐	☐	☐	
Powder (Salt)	☐	☐		☐
Crack	☐	☐		☐
Other	☐	☐		☐
Amphetamine type	☐	☐	☐	
Amphetamine	☐	☐		☐
Methamphetamine	☐	☐		☐
'Ecstasy' type	☐	☐		☐
Sedatives & Tranquillisers*	☐	☐	☐	
Barbiturates	☐	☐		☐
Benzodiazepines	☐	☐		☐
Hallucinogens	☐	☐	☐	
LSD	☐	☐		☐
Other	☐	☐		☐
Solvents & inhalants	☐	☐	☐	
Other drugs				
	☐	☐	☐	
	☐	☐	☐	
	☐	☐	☐	

Complete Q2 and Q3 only when there has been significant use in the past year (Q1 = YES)

Ranking of drugs:
Start in Q2 with 1 for the most prevalent class of drugs, 2 for the second most prevalent class, etc. If necessary, you can assign equal rank numbers to more than one class of drug.
Continue with ranking individual drug types in Q3 in order of prevalence within each drug class separately.

*Non-prescribed / non-therapeutic use only

Q4

What has been the trend over the past year in prevalence of each drug class?

Q5

What has been the trend over the past year in prevalence of each drug type?

Complete Q4 and Q5 only when there has been significant use in the past year (Q1 = YES)

Class of drugs / Type of drugs	Q4: Large increase	Q4: Some increase	Q4: No great change	Q4: Some decrease	Q4: Large decrease	Q5: Large increase	Q5: Some increase	Q5: No great change	Q5: Some decrease	Q5: Large decrease
Cannabis type	☐	☐	☐	☐	☐					
Marihuana						☐	☐	☐	☐	☐
Hashish						☐	☐	☐	☐	☐
Opioids	☐	☐	☐	☐	☐					
Heroin						☐	☐	☐	☐	☐
Opium						☐	☐	☐	☐	☐
Other						☐	☐	☐	☐	☐
Cocaine type	☐	☐	☐	☐	☐					
Powder (Salt)						☐	☐	☐	☐	☐
Crack						☐	☐	☐	☐	☐
Other						☐	☐	☐	☐	☐
Amphetamine type	☐	☐	☐	☐	☐					
Amphetamine						☐	☐	☐	☐	☐
Methamphetamine						☐	☐	☐	☐	☐
'Ecstasy' type						☐	☐	☐	☐	☐
Sedatives & Tranquillisers*	☐	☐	☐	☐	☐					
Barbiturates						☐	☐	☐	☐	☐
Benzodiazepines						☐	☐	☐	☐	☐
Hallucinogens	☐	☐	☐	☐	☐					
LSD						☐	☐	☐	☐	☐
Other						☐	☐	☐	☐	☐
Solvents & inhalants	☐	☐	☐	☐	☐					
Other drugs										
	☐	☐	☐	☐	☐					
	☐	☐	☐	☐	☐					
	☐	☐	☐	☐	☐					

*Non-prescribed / non-therapeutic use only

Q6

Do you have an estimate of drug prevalence among the general population?

Tick ONLY ONE

- ☐ **No** → Proceed to Q10
- ☐ **Yes** an estimate for the country as a whole
- ☐ **Yes** an estimate for a part of the country or a sub-population

Q7

For which year does the estimate apply?
Which part of the country or the population is covered by the estimate?

Year of the national estimate ☐☐☐☐

Year of the partial estimate ☐☐☐☐

Part of the country or sub-population for which the estimate applies

Estimated size of the reference population for which the estimate applies ☐☐☐☐☐☐☐☐

Please complete questions Q8 – Q9 for the estimate specified in Q7 above	Q8 What is the estimated LIFETIME prevalence rate per 100 among the general population? *Specify separately for the female population*		Q9 What is the estimated prevalence rate per 100 among the general population in the REPORTING YEAR? *Specify separately for the female population*	
Preferred prevalence measure			**Last 12 months**	
Prevalence measure used				
Preferred age range	**15-64 years**		**15-64 years**	
Age range used				
	All %	Females %	All %	Females %
Cannabis type				
Opioids				
Heroin				
Opium				
Other				
Cocaine type				
Powder (Salt)				
Crack				
Other				
Amphetamine type				
Amphetamine				
Methamphetamine				
'Ecstasy' type				
Sedatives & Tranquillisers*				
Barbiturates				
Benzodiazepines				
Hallucinogens				
LSD				
Other				
Solvents & inhalants				
Other drugs				

All figures should be rates per 100 of population. You do not need to add % after your figures.

Provide decimal figures. If an estimate results in a zero prevalence rate please note as 0.

If you have an estimate of the NUMBERS of users, please convert these into rates per 100 of the reference population.

If you do not have figures for the preferred age range, you should specify the age ranges that applies to your estimates.

If you do not have figures for the preferred prevalence measure for the reporting year, you should specify the prevalence measure used for your estimate.

*Non-prescribed / non-therapeutic use only

Q10

Do you have an estimate of drug prevalence among the school (youth) population?

Tick ONLY ONE

☐ **No** → Proceed to Q15

☐ **Yes**
an estimate for the country as a whole

☐ **Yes**
an estimate for a part of the country or a sub-population

Q11

For which year does the estimate apply?
Which Part of the country or sub-population is covered by the estimate?

Year of the national estimate ☐

Year of the partial estimate ☐

Part of the country or sub-population for which the estimate applies

☐

Estimated size of the reference population for which the estimate applies ☐

Please complete questions Q12 – Q14 for the estimate specified in Q10

	Q12	Q13	Q14
	What is the estimated prevalence rate per 100 among YOUNG ADOLESCENTS population in the REPORTING YEAR? ***Specify separately for the female population***	**What is the estimated LIFETIME prevalence rate per 100 among the school (youth) population?** ***Specify separately for the female population***	**What is the estimated prevalence rate per 100 among the school (youth) population in the REPORTING YEAR?** ***Specify separately for the female population***
Preferred prevalence measure	**Last 12 months**		**Last 12 months**
Prevalence measure used			
Preferred age range	**15-16 years**		
Age range used			
	All % / Females %	All % / Females %	All % / Females %
Cannabis type			
Opioids			
Heroin			
Opium			
Other			
Cocaine type			
Powder (Salt)			
Crack			
Other			
Amphetamine type			
Amphetamine			
Methamphetamine			
'Ecstasy' type			
Sedatives & Tranquillisers*			
Barbiturates			
Benzodiazepines			
Hallucinogens			
LSD			
Other			
Solvents & inhalants			
Other drugs			

All figures should be rates per 100 of population.
You do not need to add % after your figures.

Provide decimal figures. If an estimate results in a zero prevalence rate please note as 0.

If you have an estimate of the NUMBERS of users, please convert these into rates per 100 of the reference population.

You should always specify the age ranges used for the estimates.

If you do not have figures for the preferred age range of young adolescents, you should specify the age range that applies to your estimates.

If you do not have figures for the preferred prevalence measure for the reporting year, you should specify the prevalence measure used for your estimate.

*Non-prescribed / non-therapeutic use only

Q15

Has there been significant practice of injecting among drug users in the past year?

Q16

What has been the trend in injecting over the past year?

If there has been no significant practice of injecting (All drugs = NO), proceed to Q22.

	NO	YES	Large increase	Some increase	No great change	Some decrease	Large decrease
All drugs (not differentiated)	☐	☐	☐	☐	☐	☐	☐
Heroin	☐	☐	☐	☐	☐	☐	☐
Other opioids	☐	☐	☐	☐	☐	☐	☐
Cocaine type	☐	☐	☐	☐	☐	☐	☐
Amphetamine	☐	☐	☐	☐	☐	☐	☐
Methamphetamine	☐	☐	☐	☐	☐	☐	☐
'Ecstasy' type	☐	☐	☐	☐	☐	☐	☐
Other drugs							
_____	☐	☐	☐	☐	☐	☐	☐
_____	☐	☐	☐	☐	☐	☐	☐
_____	☐	☐	☐	☐	☐	☐	☐

With 'sharing' needles or syringes we mean 'using a needle or syringe that has been used previously by someone else'.

Q17

Has there been significant practice of sharing needles or syringes among drug injectors in the past year?

☐ **No** → Proceed to Q19

☐ **Yes**

Q18

What has been the trend over the past year in sharing needles or syringes among drug injectors?

Large increase	Some increase	No great change	Some decrease	Large decrease
☐	☐	☐	☐	☐

Q19

Do you have an estimate of the percentage of drug injectors among drug users?

Tick ONLY ONE

☐ **No** → Proceed to Q23

☐ **Yes**
an estimate for the country as a whole

☐ **Yes**
an estimate for a part of the country or a subgroup of drug users

Q20

For which year does the estimate apply? Which part of the country or subgroup of drug users is covered by the estimate?

Year of the national estimate ☐

Year of the partial estimate ☐

Part of the country or subgroup of drug users for which the estimate applies

☐

Estimated size of the reference population for which the estimate applies ☐

Please complete question Q21 for the estimate specified in Q20

Q21

What is the estimated PERCENTAGE of drug injectors among all drug users?

If there has been no significant practice of sharing (Q17=NO), proceed to Q23

Q22

What is the estimated PERCENTAGE of drug injectors that have shared needles or syringes in the past year?

	Q21	Q22
All drugs (not differentiated)	☐	☐
Heroin	☐	
Other opioids	☐	
Cocaine type	☐	
Amphetamine	☐	
Methamphetamine	☐	
'Ecstasy' type	☐	
Other drugs		
☐	☐	
☐	☐	
☐	☐	

Q23

Does your country make a distinction between drug users in general and drug users who are considered particularly problematic, chronic or in need of help?

☐ **No** → Proceed to Q29

☐ **Yes**

Q24

What has been the trend over the past year in "severe / problematic" drug use?

Large increase	Some increase	No great change	Some decrease	Large decrease
☐	☐	☐	☐	☐

Q25

Do you have an estimate of drug users, who are considered particularly problematic, chronic users or in need of help?

Tick ONLY ONE

☐ **No** → Proceed to Q29

☐ **Yes**
an estimate for the country as a whole

☐ **Yes**
an estimate for a part of the country or a subgroup of drug users

Q26

For which year does the estimate apply?
Which part of the country or which subgroup of drug users is covered by the estimate?

Year of the national estimate ☐

Year of the partial estimate ☐

Part of the country or subgroup of drug users for which the estimate applies

☐

Estimated size of the reference population for which the estimate applies ☐

Please complete questions Q27 – Q28 for the estimate specified in Q26

Q27

What is the estimated number of "severe / problematic" drug users?

☐

Q28

Which definition of "severe / problematic users" applies to the estimated number of Q27 and how is the estimate calculated?

☐

Q29

Have new drugs or new patterns of drug use been reported in the past year?

☐ No → Proceed to Q31

☐ Yes

Q30

Which new drugs or new patterns of use have been reported?

Q31

Have new groups of drug users been reported in the past year?

☐ No → Proceed to Q33

☐ Yes

Q32

Which new groups of drug users have been reported and in relation to which types of drugs?

Please use the space below to document any other developments in prevalence and patterns of drug abuse in your country over the past year.

Q33

Have there been reports about prevalence of infections among drug injectors in the past year?

Q34

What has been the trend over the past year in prevalence of infections among drug injectors?

	NO	YES	Large increase	Some increase	No great change	Some decrease	Large decrease
Hepatitis B	☐	☐	☐	☐	☐	☐	☐
Hepatitis C	☐	☐	☐	☐	☐	☐	☐
HIV	☐	☐	☐	☐	☐	☐	☐

Q35

Do you have an estimate of drug users having any of the infections mentioned in the table above?

Tick ONLY ONE

☐ **No** → Proceed to Q39

☐ **Yes**
an estimate for the country as a whole

☐ **Yes**
an estimate for a part of the country or a subgroup of drug injectors

Q36

For which year does the estimate apply?
Which part of the country or which subgroup of drug injectors is covered by the estimate?

Year of the national estimate ☐

Year of the partial estimate ☐

Part of the country or subgroup of drug injectors for which the estimate applies

☐

Estimated size of the reference population for which the estimate applies ☐

Please complete questions Q37 – Q38 for the estimate specified in Q36

Q37

What is the estimated NUMBER of infected drug injectors?

Q38

What is the estimated PERCENTAGE of infected persons among drug injectors?

	Q37	Q38
Hepatitis B	☐	☐
Hepatitis C	☐	☐
HIV	☐	☐

	Q39 Have there been reports about drug-related deaths in the past year?		Q40 How are drugs ranked in order of the primary cause in drug-related deaths?	Q41 What has been the trend over the past year in drug-related deaths?				
	NO	YES	Put in numerical order	Large increase	Some increase	No great change	Some decrease	Large decrease
All drugs (not differentiated)	☐	☐		☐	☐	☐	☐	☐
Heroin	☐	☐	☐	☐	☐	☐	☐	☐
Other opioids	☐	☐	☐	☐	☐	☐	☐	☐
Cocaine type	☐	☐	☐	☐	☐	☐	☐	☐
Amphetamine	☐	☐	☐	☐	☐	☐	☐	☐
Methamphetamine	☐	☐	☐	☐	☐	☐	☐	☐
'Ecstasy' type	☐	☐	☐	☐	☐	☐	☐	☐
Other drugs								
☐	☐	☐	☐	☐	☐	☐	☐	☐
☐	☐	☐	☐	☐	☐	☐	☐	☐
☐	☐	☐	☐	☐	☐	☐	☐	☐

Ranking of drugs as primary cause in drug-related deaths:
Start with 1 for the drug most frequently the primary cause in drug-related deaths, 2 for the second most frequent primary cause, etc. If necessary, you may assign equal rank numbers to more than one drug.

Q42

Do you have an estimate of the number of drug-related deaths?

Tick ONLY ONE

☐ **No** → Proceed to Q48

☐ **Yes**
an estimate for the country as a whole

☐ **Yes**
an estimate for a part of the country or a sub-population

Q43

For which year does the estimate apply? Which part of the country or sub-population is covered by the estimate?

Year of the national estimate ☐

Year of the partial estimate ☐

Part of the country or sub-population for which the estimate applies

☐

Estimated size of the reference population for which the estimate applies ☐

Please complete questions Q44 – Q47 for the estimate specified in Q43	Q44 What is the estimated TOTAL number of drug-related deaths?	Q45 What is the estimated number of FATAL DRUG OVERDOSES ONLY?	Q46 What is the estimated number of Drug-related AIDS DEATHS?	Q47 What is the estimated number of drug-related OTHER DEATHS (excluding fatal drug overdoses and AIDS deaths)?
All drugs (not differentiated)	☐	☐	☐	☐
Heroin	☐	☐	☐	☐
Other opioids	☐	☐	☐	☐
Cocaine type	☐	☐	☐	☐
Amphetamine	☐	☐	☐	☐
Methamphetamine	☐	☐	☐	☐
'Ecstasy' type	☐	☐	☐	☐
Other drugs				
☐	☐	☐	☐	☐
☐	☐	☐	☐	☐
☐	☐	☐	☐	☐

Q48

Have people received treatment for drug problems in the past year?

Q49

How are drugs ranked in order of the primary cause of receiving treatment?

Q50

What has been the trend over the past year in the numbers of people receiving treatment?

Ranking of drugs as primary cause of treatment:
Start with 1 for the drug most frequently the primary cause of treatment, 2 for the second most frequent primary cause, etc. If necessary, you may assign equal rank numbers to more than one drug.

	NO	YES	Put in numerical order	Large increase	Some increase	No great change	Some decrease	Large decrease
All drugs (not differentiated)	☐	☐		☐	☐	☐	☐	☐
Cannabis type	☐	☐	☐	☐	☐	☐	☐	☐
Heroin	☐	☐	☐	☐	☐	☐	☐	☐
Other opioids	☐	☐	☐	☐	☐	☐	☐	☐
Cocaine type	☐	☐	☐	☐	☐	☐	☐	☐
Amphetamine	☐	☐	☐	☐	☐	☐	☐	☐
Methamphetamine	☐	☐	☐	☐	☐	☐	☐	☐
'Ecstasy' type	☐	☐	☐	☐	☐	☐	☐	☐
Other drugs								
☐	☐	☐	☐	☐	☐	☐	☐	☐
☐	☐	☐	☐	☐	☐	☐	☐	☐

Q51

Do you have an estimate of the number of people receiving treatment for drug problems?

Tick ONLY ONE

☐ **No** → Proceed to Q25

☐ **Yes**
an estimate for the country as a whole

☐ **Yes**
an estimate for a part of the country or a selection of treatment facilities

Q52

For which year does the estimate apply?
Which part of the country or selection of treatment facilities is covered by the estimate?

Year of the national estimate ☐

Year of the partial estimate ☐

Part of the country for which the estimate applies

Types of treatment facilities included and/or excluded in the estimate

Please complete questions Q53 – Q58 for the estimate specified in Q52

	Q53 What is the estimated NUMBER of people receiving treatment for drug problems?	Q54 What is the estimated PERCENTAGE of people receiving treatment for the FIRST TIME EVER among people in treatment?	Q55 What is the estimated PERCENTAGE of FEMALES among people in treatment	Q56 What is the estimated MEAN AGE of people in treatment?	Q57 What is the estimated PERCENTAGE of DRUG INJECTORS among people in treatment?
All drugs (not differentiated)					
Cannabis type					
Heroin					
Other opioids					
Cocaine type					
Amphetamine					
Methamphetamine					
'Ecstasy' type					
Other drugs					

Q58

Which definition of "people treated for drug problems" applies to the figures in the columns of Q53 – Q57 above?

	Tick as Appropriate	Tick as Appropriate	Tick as Appropriate	Tick as Appropriate	Tick as Appropriate
People starting treatment during the year	☐	☐	☐	☐	☐
People receiving treatment during the year	☐	☐	☐	☐	☐
People in treatment at census date in the year	☐	☐	☐	☐	☐
People discharged from treatment during the year	☐	☐	☐	☐	☐
Other	☐	☐	☐	☐	☐

Q59

Has your country capacity with regard to data collection instruments specified below?

Q60

How would you qualify the present suitability of these instruments for making national estimates about the drug situation?

	Q59 NO	Q59 YES	Q60 Poor	Q60 Moderate	Q60 Good
Registers					
Specialised treatment register	☐	☐	☐	☐	☐
Registers on drug-related morbidity	☐	☐	☐	☐	☐
Registers on drug-related mortality	☐	☐	☐	☐	☐
Survey instruments					
Prevalence surveys among the general population	☐	☐	☐	☐	☐
Prevalence surveys among school populations	☐	☐	☐	☐	☐
Surveys among drug users	☐	☐	☐	☐	☐
Qualitative research instruments					
Rapid Situation Assessment	☐	☐	☐	☐	☐
Other ☐	☐	☐	☐	☐	☐

Q61

If applicable, what are the main obstacles for implementation or improvement of data collection instruments suitable for making national estimates about the drug situation?

Reports

Please list below relevant national reports or major studies about the extent, patterns or trends in drug abuse in your country, published in the past year. ***Specify author, title and year of publication. Attach copies of documents and reports if possible.***

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

Additional information

Please use the space below to add notes of clarification to any of the information contained in this questionnaire or to document any issue that you wish to draw to the attention of UNDCP.